Substance P is required for the pathogenesis of EMCV infection in mice

Insights

Substance P (SP) is essential for the development of viral myocarditis. Blocking SP signaling completely protected mice from mortality and cardiac damage caused by encephalomyocarditis virus (EMCV) infection.

Area of Science:

  • Cardiovascular Research
  • Immunology
  • Molecular Biology

Background:

  • Myocarditis, often viral, causes heart failure in young individuals.
  • Viral myocarditis involves cardiac inflammation and cell death, with incomplete understanding of its molecular basis.
  • Proinflammatory cytokines and Substance P (SP) are implicated in viral infections and myocarditis pathogenesis.

Purpose of the Study:

  • To investigate the role of Substance P (SP) in the pathogenesis of encephalomyocarditis virus (EMCV)-induced myocarditis.
  • To determine if targeting SP signaling could be a therapeutic strategy for viral myocarditis.

Main Methods:

  • Encephalomyocarditis virus (EMCV) infection model in wild-type and SP precursor knockout mice.
  • Measurement of SP levels, mortality rates, heart-to-body weight ratio, and cardiac histopathology (inflammation, necrosis, apoptosis, hypertrophy).

Main Results:

  • EMCV infection significantly increased SP levels (61-fold) and mortality (51%) in wild-type mice.
  • Infected wild-type mice exhibited increased heart size, cardiac inflammation, necrosis, and cardiomyocyte apoptosis/hypertrophy.
  • SP precursor knockout mice were fully protected against EMCV-induced mortality, cardiac pathology, and cellular changes.

Conclusions:

  • Substance P (SP) plays a critical, essential role in the pathogenesis of EMCV-induced myocarditis.
  • Targeting the SP signaling pathway represents a promising therapeutic avenue for treating viral myocarditis in humans.